

Rec'd PERTH 03 DEC 2004

516, 864

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT CO-OPERATION TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



A standard linear barcode is located at the bottom of the page, spanning most of the width. It is used for tracking and identification of the journal issue.

(43) International Publication Date
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number
WO 2004/002294 A2

(51) International Patent Classification⁷:

A61B

(74) Agents: **ORTEGA, James, H. et al.**; Baker & McKenzie, Suite 2300, 2001 Ross Avenue, Dallas, TX 75201 (US).

(21) International Application Number: PCT/US2003/020587

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

(22) International Filing Date: 27 June 2003 (27.06.2003)

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


(30) Priority Data: 60/392,191 28 June 2002 (28.06.2002) US

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,

[Continued on next page]

(54) Title: PLASMA OR SERUM MARKER AND PROCESS FOR DETECTION OF CANCER



(57) Abstract: This disclosures provide, in one aspect, a method for detecting non-clinically diagnosed cancer in patient. In one embodiment, the method includes extracting blood serum or plasma from the patient, and then detecting beta-catenin RNA in the blood serum or plasma. In addition, in this embodiment, the method includes determining the presence of the cancer based on the detected beta-catenin RNA. In another aspect, this disclosure provides another embodiment of a method for detecting non-clinically diagnosed cancer in a patient. In this embodiment, the method includes extracting blood serum or plasma from the patient, and then detecting beta-catenin DNA in the blood serum or plasma. In addition, in this embodiment, the method includes determining the presence of the cancer based on the detected beta-catenin DNA. Related methods for detecting non-clinically diagnosed cancer in a patient comprising detecting beta-catenin-associated gene RNA, and beta-catenin-associated gene DNA, in the blood serum or plasma are also disclosed.

BEST AVAILABLE COPY



JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PLASMA OR SERUM MARKER AND PROCESS
FOR DETECTION OF CANCER

5

CROSS-REFERENCE TO RELATED APPLICATION

This non-provisional International Patent Application claims priority from U.S. Provisional Application Serial No. 60/392,191, filed on June 28, 2002, and entitled "Plasma or Serum Marker and Process for Detection of Cancer", which is commonly owned with the present application and incorporated herein by reference 10 for all purposes.

FIELD OF THE INVENTION

The present invention relates to a PCR based process in detection of blood plasma or serum marker for diagnosis, early detection, monitoring and population 15 screening for cancer and, more particularly, detection of β -catenin RNA and DNA in blood plasma or serum for colorectal cancer.

BACKGROUND OF THE INVENTION

Colorectal cancer (CRC) is one of the most common malignancies worldwide. 20 The number of new cases of CRC has been increasing rapidly since 1975. More than 70% of CRC cases develop from sporadic adenomas or adenomatous polyps. Early detection and surgical removal of polyps is believed to be the most effective way to prevent benign polyps from developing into malignant tumors and thereby reducing mortality caused by CRC.

25 Traditional screening methods for colorectal cancer include sigmoidoscopy, fecal occult blood testing, colonoscopy and double contrast barium enema. However, these traditional methods suffer from limitations and are invasive, high cost, of low predictive value or result in low detection rates. For example, WO0142504, the teachings of which are incorporated herein by reference, discloses a multi-reaction 30 process for detection of extracellular tumor associated nucleic acid in blood plasma or serum. Further advances are desirable.

β-catenin protein was initially identified through its interaction with cadherins. Recent evidence shows that it acts as a transcriptional factor and plays a key role in the Wnt-signaling pathway (Willert & Nusse, 1998). It has been demonstrated that accumulation of cytoplasmic and nuclear β-catenin signaling is 5 tightly associated with the genesis of a wide variety of tumors. (Morin, 1999).

It has been discovered that using immunohistochemical staining that levels of nuclear β-catenin are highly correlated with the purported sequential stages in colorectal carcinogenesis with positive staining observed in 0% of normal tissues, 8% of polyps, 92% of adenomas and 100% of carcinomas. It has been further discovered 10 that the nuclear β-catenin signal appears to clearly differentiate the polyps (non-adenomatous polyps) from adenomas (adenomatous polyps). This would be a useful marker for clinical diagnosis, or early detection of CRC, with the adenoma being considered as endpoint for risk factor. However, this diagnostic method based on the evaluation of nuclear β-catenin requires coloscopic procedure, then surgical removal 15 of the suspected tissues.

Accordingly, there is a need for an effective, less invasive, more accurate test for early detection of cancer. The present invention meets this need.

SUMMARY OF THE INVENTION

20 The present invention provides a PCR (Polymerase Chain Reaction) based method or process in the detection of serum or plasma marker RNA and DNA related to β-catenin providing an effective, less evasive and more accurate test for the diagnosis, early detection, monitoring, and population screening of colorectal and other cancer types. It will be appreciated that this method of detection of β-catenin 25 RNA and DNA in blood serum can be applied to other plasma and serum RNA and DNA encoded for β-catenin associated proteins. In one embodiment, the RNA or DNA is derived from genes encoded beta-catenin, alpha-catenin, E-catherin and other beta catenin associated proteins.

30 The process of the present invention comprises detecting blood serum or plasma RNA or/and DNA from a human or animal as a tool in the diagnosis, early detection, monitoring, treatment and population screening of neoplastic diseases at various progression and clinical stages. One advantage of the present invention is the

non-invasive nature of the method, and a second advantage is improved accessibility of sample collections and sensitivity

Details of multiple embodiments of the invention are set forth below. These embodiments are for illustrative purposes only and the principles of the invention can 5 be implemented in other embodiments. Other features and advantages of this invention will become apparent from the following description and examples.

BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding, reference is now made to the following 10 detailed description taken in conjunction with the accompanying drawings. It is emphasized that some components may not be illustrated for clarity of discussion. Reference is now made to the following descriptions taken in conjunction with the accompanying drawings, in which:

FIG. 1a, FIG. 1b and FIG. 1c illustrate detection of β -catenin RNA from 15 plasma of colorectal carcinoma patients using RT-PCR.

FIG. 2a and FIG. 2b illustrate detection of blood β -catenin RNA from patients for colorectal adenoma using RT-PCR.

FIG. 2c illustrate detection of blood β -actin RNA from patients for colorectal adenoma using RT-PCR.

20 FIG. 3a, FIG. 3b, FIG. 3c, FIG. 3d, and FIG. 3e illustrate detection of serum β -catenin DNA from patients with adenomas or carcinomas and normal controls.

DETAILED DESCRIPTION OF THE INVENTION

The search for sensitive and specific biomarkers for early detection of 25 colorectal cancer has been discovered in the present invention. The advanced understanding of the molecular mechanism underlying the carcinogenesis of colorectal cancer has helped to identify a few oncogenes and tumor suppressors as potential clinical biomarkers of colorectal cancer development and early detection. These include *k-ras*, APC, p53, MCC, DCC genes. However, none of the candidate

5 markers alone can provide satisfactory detection rate. The recent PCR-based detections of *K-ras*, APC and p53 mutations of in the blood samples of cancer patients have indeed greatly increased the accessibility of sample collections. However, the rate of detection is generally lower than that observed with primary tumors. For instance, in a study of 14 patients with colorectal cancer, out of seven confirmed *k-ras* mutations, the same mutation was found in 6 patients' serum. The serum positive rate was 86% (Anker 1997). Another study showed that serum positive rate for loss of heterozygosity (LOH), microsatellite instability, *k-ras* and p53 mutations were 0, 0, 19, and 70% respectively (Hibi 1998). Similar results have been 10 obtained with other types of cancers, in which the genetic alterations found in serum DNA (deoxyribonucleic acid) tend to be lower than those found in primary tumors (Kopreski 2001; Sozzi 1999; von Knobloch 2001).

15 Compared with other related studies, the use of serum β -catenin DNA in the present invention for early detection of colorectal cancer may fulfill the criteria of being a marker for early detection: 1. The marker is differentially present in blood of normal, and premalignant or tumor-bearing patients; 2. The method has the capacity to detect adenomatous polyps as small as 4 mm in diameter; 3. The method is simple with high degree of accuracy; 4. The amount of blood sample required is small (2-5 ml), and sample collection is through non-invasive, normal blood-drawing procedure. 20 Thus, it has been suggested in the present invention that β -catenin DNA levels, along with β -catenin RNA levels, in blood serum or plasma could provide one answer to the quest for an effective, accurate test for colorectal cancer, using equipment and reagents already readily available—hence appropriate for widespread population screening, early detection, and disease monitoring of this increasingly common 25 cancer.

EXAMPLES

30 The following examples are intended to illustrate, but not limit the embodiments of the invention described herein. Specifically, in the following discussion, numerous specific details are set forth to provide a thorough understanding of the present disclosure. However, those skilled in the art will appreciate that some of the techniques herein may be practiced without such specific details. In other instances, well-known elements or specific details have been

condensed or omitted altogether inasmuch as detail discussions of these features are not considered necessary to obtain a complete understanding of the disclosure, and are considered to be within the understanding of persons of ordinary skill in the relevant field of art.

5

Example 1

* β -catenin RNA was detected in all plasma samples of patients with colorectal carcinoma.

To detect the presence of plasma β -catenin, RT-PCR (reverse transcription-polymerase chain reactions) were preformed on two blood samples from patients with carcinoma using Primer #1 that would yield a 224 bp of exon 3 region of the gene. An RNA sample extracted from carcinoma tumor expressing high level of β -catenin was included as positive control. Results showed that two plasma and the positive control RNA samples yielded a 224 bp band in the presence, but not in the absence of, reverse transcriptase (RT) in the reaction (FIG. 1a). RT-PCR analysis was preformed on the other 10 plasma RNA samples using the intron spanning primers (Primer#2, Table 2).

Data showed that a 250 bp fragment was clearly detected in all 10 patient plasma samples (FIG. 1a, lanes 1-10), suggesting the presence of β -catenin RNA in the circulating blood of carcinoma patients. The data also showed that the reaction is RT-dependent (FIG. 1b, lane 12). A genomic DNA sample was included as a positive control for PCR reaction and a 450 bp band appeared as expected (FIG. 1b, lane 11).

To prove that the 250 bp band was derived from the RNA, instead of DNA templates in the plasma, tests were performed on the three remaining plasma RNA samples without prior treatment with DNase I.

25 Two PCR products, a 250 bp band amplified from RNA and a 450 bp band amplified from the DNA contaminating plasma RNA extract, appeared on the gel. All three samples yielded both 250 and 450 bp bands in the presence of RT (FIG. 1b, lanes13-15), and a single 450 bp band was observed from a RNase treated DNA sample in the absence of RT (FIG. 1b, lane 1).

30 Fifteen patients were tested with carcinoma using three slight different experimental settings described above, and the data showed that 15 in 15 patients were clearly positive for plasma β -catenin.

Example 2

*Plasma RNA was present at high rates in patients with adenomas, but not in healthy individuals.

Seventeen plasma samples were screened for β -catenin RNA from individuals with suspected adenomas. Of the 17 plasma samples from individuals with suspected adenomas screened for β -catenin RNA, 11 were plasma positive, indicated by the presence of a 250 bp RT-PCR product; 6 were found negative (FIG. 2a, lanes 1-11; FIG. 2b, lanes 1-6). RT-PCR assays were performed on the 6 negative samples using primers specific for β -actin sequences (Table 2, Primer#3). β -actin RNA was detected in all six plasma samples (FIG. 2c, lanes 1-6), indicating the six plasma RNA extracts were in amplifiable quality. Of the 6 patients with negative β -catenin signals (Table 1, Patients#10, 14, & 16), biopsy later confirmed that three were diagnosed with adenoma, two had granulation tissues, and the other had a dilated lymphatic space (Table 1, Patients#1-3). The percentage of detection among adenoma patients was 79% (11 of 14). Parallel RT-PCR analyses were performed on 10 healthy subjects. Nine of the ten healthy controls showed negative plasma β -catenin signals, but all showed positive β -actin RNA signals (FIG. 2d & FIG 2e, lanes 1-10). Only 1 of them had a rather weak positive signal (FIG. 2d, lane 10).

In summary, the presence of β -catenin was examined in the blood plasma of 32 patients with confirmed carcinoma or adenoma using RT-PCR analysis. Results showed that 100% (15 of 15) of patients with carcinoma, 79% (11 of 14) of patients with adenoma and 10% (1 of 10) healthy volunteers carried β -catenin RNA in their circulating blood. It is worthy to mention that the apparently healthy subject with weak plasma β -catenin RNA had been suffered from long-standing colorectal discomfort, occasionally with fecal blood and diarrhea, although no abnormality or ulceration colitis was detected in an endoscopic examination. Three patients with suspected adenoma at admission were also tested for plasma β -catenin. All three patients who were later confirmed by biopsy to be free of adenoma were negative for plasma signal.

It has been shown that free DNA is present in the circulating blood of patients with disorders and cancers, and this DNA can be detected using PCR assay.

Furthermore, reports have showed that genetic alterations of specific gene sequences can be detected in the serum of cancer patients (Anker P 1997; Hibi K

1998; Kopreski MS 2001; Sozzi G 1999; von Knobloch R 2001). Aside from plasma DNA, sequence-specific RNAs have also been detected in cancerous, but not healthy, individuals using RT-PCR analysis (Kopreski MS 1999; Lo KW, 1999; Chen XQ 2000). Whether the PCR method for the detection of plasma and serum DNA or RNA 5 can be implemented for cancer diagnosis and prognosis will mainly depend on how well the data can validate the status of the tumor or even the pre-cancerous lesions. For instance, carcinoembryonic antigen (CEA) is expressed widely in a variety of cancers and in some normal tissue including colonic tissues. Along with carbohydrate antigen 19-9 (CA 19-9), these are the two most common tumor markers in the 10 management of patients with CRC. In general, CEA marker yields positive detection rates ranging from 40 to 60% by conventional immunochemical assay for protein content. The use of RT-PCR for serum CEA RNA detection have improved the detection rate from 35% to around 70% (Guadagni, 2001). Another recent study has showed that tyrosine mRNA is present in the serum of 60% (4 of 6) patients with 15 malignant melanoma, but not in any normal control serum (Kopreski, 1999). In our current study, the positive rate for CRC detection is 100% for patients with carcinoma and 79% for patients with adenoma. Thus, the plasma β -catenin RNA seems to be an effective serum marker for CRC detection.

At present, the only non-invasive method for CRC screening is fecal occult 20 blood testing (FOBT). Several studies found that screening with FOBT in average and high-risk patients reduced the mortality rate by 16%. The limitation of the test, however, is the low predictive rate (less than 20%). The other method used for CRC screening, in particular for early detection of adenomas, is flexible sigmoidoscopy, which is claimed to have reduced the mortality rate by 70% in few of the case-control 25 studies (for reviews, see Scotiniotis I, 1999). The test is sensitive and specific; however, it is invasive in nature. In this regard, the RT-PCR-based method for the detection of serum β -catenin may indeed provide an ideal tool for CRC screening of average and high-risk individuals. This method can be applied to monitoring post-operation and chemotherapy patients. Since β -catenin is also known to be involved in 30 other types of cancer, our current invention for detection serum or plasma β -catenin can be extended for the detection, monitoring, screening of cancers with different tissue origins. This is the first time the presence of plasma β -catenin RNA has been reported and been suggested to have diagnostic value.

Example 3

*Immunohistochemical staining of nuclear β -catenin signals of the adenoma and carcinoma tissues.

5 In more than 200 cases examined, 92% of adenomas and 100% of carcinomas, but none of the normal tissues showed elevated nuclear β -catenin. To determine the nuclear β -catenin signals of the adenomas and carcinomas obtained from patients derived from Examples 1 & 2, paraffin-embedded tissue blocks of adenoma and carcinoma of 32 patients were sectioned and examined for nuclear β -catenin. The 10 immunohistochemical staining was scored based on both the intensity and the percentage positive cells. Table 2 showed that nuclear translocation of β -catenin was observed in all tissue specimens.

Example 4

15 *Quantification of blood β -catenin RNA in healthy individuals and patients with adenoma or carcinoma using real time RT-PCR technology.

The quantitative difference in plasma β -catenin signal between adenoma and carcinoma patients was investigated using real-time reverse transcriptase-PCR (RT-PCR). The results showed that the average copy number of β -catenin mRNA was 30 fold higher in adenoma (n=12; 3 negative; 8 positive: mean, 1.1×10^3 ; ranging from 0.69×10^3 to 1.80×10^3) and 598 fold higher in carcinoma (n=18; mean, 2.2×10^4 ranging from 0.67×10^4 to 4.4×10^4) patients than the normal individuals ((n=14; mean, 36 ranging from 0 to 169). The copy number of β -catenin mRNA in carcinoma patients was 19 fold higher than in adenoma patients. These quantification analysis provide a 25 clear evidence that the plasma β -catenin mRNA are present differentially and can be used as a diagnostic tool to differentiate healthy subject, adenoma and carcinoma patients.

Example 5

30 *Detection of β -catenin DNA in the serum of patients with colorectal adenoma and carcinoma.

PCR analysis was first performed with serum DNA samples extracted from colorectal carcinoma patients. The results showed that a 359 bp band was observed in

all 15 serum DNA samples (FIG. 3a, lanes 1 to 16). Ten patients were tested with confirmed adenoma ranging from mild to severe dysplasia. Positive band was detected in 9 of 10 patients (FIG. 3b, lanes 1-11). The detection rate was 90%. The only negative case (FIG. 3b, lane 8) was amplifiable as it yielded positive 156 bp band after amplification with RET specific primers (FIG. 3d, lower panel, lane 13). PCR amplification of β -catenin was also performed on 10 healthy volunteer controls. None of the serum samples showed positive signals for β -catenin, while positive signals were clearly detected using RET specific primers (FIG. 3c, lanes 1 to 10; & 1D, lanes 1-11). In addition, a known positive carcinoma serum sample was carried out in parallel and showed typical 359 bp band on the agarose gel (FIG. 3c, lane 11). Lane 12 of FIG. 3c & FIG. 3d are the negative control for PCR reaction.

The data showed, for the first time, that serum β -catenin DNA is detectable in all patients with colorectal carcinoma and in 9 out of 10 patients with colorectal adenoma, while all 10 healthy individuals were free of serum β -catenin DNA. This result suggests that the presence of β -catenin DNA in the blood is significantly correlated with the existence of cancer at both preneoplastic and malignant stages, which may also suggest that the circulating β -catenin originated from the adenoma or carcinoma tissue of the patients. The ten adenoma patients, the individual (Patient #9, Table 4) negative in serum β -catenin had the smallest adenoma in this example (3.5 mm in diameter, 48 mm³). Patient with the next smallest size of adenoma (63 mm³) showed PCR amplifiable β -catenin DNA in the blood, suggesting that the sensitivity of the current method would allow us to detect premalignant adenomatous polyps at least as small as 63 mm³. Quantification of the copy number of β -catenin DNA in the samples using real-time PCR analysis is suggested. The findings indicate that measuring the levels of β -catenin DNA in the blood provides a highly sensitive but noninvasive method for early detection of colorectal cancer. This method may be extended to cancers of different tissue origins.

Referring now to the drawings, FIG. 1 collectively shows detection of β -catenin RNA from plasma of colorectal carcinoma patients using RT-PCR. More specifically, FIG. 1a shows RT-PCR amplification of β -catenin using β -catenin exon primers. Lanes 1-4, RT-PCR reactions of blood RNA samples isolated from two carcinoma patients in the presence (Lane 1 & 3) and absence (Lane 2 & 4) of RT

enzyme; Lane 5, mRNA extracted from carcinoma specimen expressing β -catenin as a positive control; Lane 6, a buffer control. M: RNA markers. FIG. 1b shows RT-PCR amplification of β -catenin using β -catenin intron-spanning primers. Lanes 1-10, DNAase-treated plasma RNAs isolated from ten carcinoma patients; Lane 11, 5 genomic DNA as a positive control for PCR reaction; Lane 12, a buffer control. Lanes 13-17, Samples derived from Lanes 8-12 respectively without prior DNAase treatment. FIG. 1c shows Lane 1-3, β -catenin RNA (250 bp) isolated from three patients by RT-PCR with intron-spanning primers without DNAase treatment ; lane 4, positive DNA control; lane 5, negative buffer control. M: DNA markers.

10 FIG. 2 shows detection of blood β -catenin (FIG. 2a & FIG. 2b) & β -actin (FIG. 2c) RNA from patients suspicious for colorectal adenoma (FIG 2a-2c) using RT-PCR. A. Lanes 1-17, plasma RNAs isolated from 17 patients; Lane 18, positive DNA control; Lane 19, negative control. Detection of blood β -catenin (FIG 2d) & β -actin (FIG 2e) RNA from plasma of ten healthy objects (Lanes 1-10). Lane 11, 15 positive DNA control, Lane 12, negative buffer control.

FIG. 3 shows detection of serum β -catenin DNA from patients with adenomas or carcinomas and normal controls. FIG. 3a, FIG. 3b and FIG. 3c show PCR analyses with β -catenin specific primers were performed with serum samples isolated from patients with colorectal carcinoma: FIG 3a, lanes 1-15; with colorectal adenoma: 20 FIG 3b, lanes 1-10; from healthy individuals: FIG 3c, lanes 1-10. FIG 3d: PCR reactions with RET specific primers were performed with serum samples with negative β -catenin signal. Lanes 1-10, same healthy individual serum samples shown in FIG 3c; FIG 3d, lane 13: the same serum sample shown in Panel FIG 3b, lane 8. Positive control genomic DNA isolated from carcinoma tumor: FIG 3a, lane 16; FIG 25 3b, lane 11; FIG 3c, lane 11; FIG 3d, lane 11. Negative cell free control: FIG 3a, lane 17; FIG 3b, lane 12; FIG 3c, lane 12; FIG 3d, lane 12. M: Hae III λ DNA marker.

Techniques applied:

Blood samples and RNA extraction

30 A 6-ml blood sample was collected from each patient by transcutaneous needle into 8-ml Vacutainers containing EDTA lithium heparin. Blood samples were centrifuged at 4800 rpm for 8 min. Plasma was aliquoted into polypropylene tubes

and stored at -80°C for later RNA extraction. RNA was extracted from plasma sample using TRIZOL Kit (Life Technologies, USA), then purified with RNeasy column (Qiagen, Germany) according to the manufacturer's manuals. In brief, 2ml of each plasma sample was mixed with 1.6 ml TRIZOL and 0.4 ml chloroform, 5 centrifuged at 12,000 rpm for 15 min at 4°C. The aqueous phase was collected for RNA extraction using the RNeasy column. The isolated RNA was dissolved in 15 µl of DEPC-treated water. The RNA samples were further treated with PCR grade of deoxyribonuclease I (DNase I)(Life Technologies). In the reaction, 1 µl each of 10 x DNase I reaction buffer and DNase I were added into the 15 µl of RNA sample and 10 incubated at room temperature for 15 min followed by inactivation of DNase I by the addition of 1 µl of 15 mM EDTA and heated at 65°C for 5 min, then chilled in ice before RT-PCR reaction.

Primers and RT-PCR reactions of blood RNA samples

The detection of plasma β -catenin was performed using RT-PCR assay with a 15 set of primers including intron sequence spanning between exon 3 and 4 of β -catenin gene (Table 1). For comparison, a separate set of primers sequences within exon 3 of the β -catenin gene was also incorporated in some PCR reactions. The reverse transcription reaction was performed according to the manufacturer's guides (Qiagen, Germany). PCR was carried out using reagents supplied in a GeneAmp DNA 20 Amplification Kit using AmpliTaq Gold as the polymerase (Perkin-Elmer Corp., Foster City, CA). The parameters used in PCR were 40 cycles with initial denaturation at 95°C for 10 min, followed by 94 °C for 1 min 15 s, 59 °C (β -catenin) for 1 min 30 s, 72°C for 1 min 30 s, with a final extension step of 72°C for 10 min. PCR products were analyzed by 1.5% agarose gel electrophoresis and ethidium 25 bromide staining. A negative (water) control was included in each RT-PCR assay. All samples with negative results were subjected to RT-PCR assay for β -actin RNA using intron-spanning primers (Table 3) as a control for the amplifiability of plasma-extracted RNA.

DNA extraction

30 Blood sera were removed from the supernatants of clotted blood samples and were centrifuged at 4800 rpm for 8 minutes, followed by gently aliquoting of serum

into polypropylene tubes and storage at -20°C for later DNA extraction. DNA was isolated from 200 µl serum using QIAamp DNA Mini Kit (Qiagen, Hilden Germany) according to the manufacturer's protocol. The DNA samples,, were eluted with 50 µl of ddH2O.

5

Primers and PCR reactions of blood DNA samples

The detection of β-catenin was performed using PCR assay with set of primers franking the 2nd and the 3rd introns of β-catenin gene (Table 3). The PCR was carried out using reagents supplied in a GeneAmp DNA Amplification Kit using AmpliTaq Gold as the polymerase (Perkin-Elmer Corp., Foster City, CA). The parameters used 10 in PCR were 40 cycles with initial denaturation at 95°C for 10 min, followed by 94 °C for 1 min and 15 s, 57 °C (β-catenin) and 69°C (RET) for 1 min 30 s, 72°C for 1 min 30 s, with a final extension step of 72°C for 10 min. PCR products were analyzed by 1.5% agarose gel electrophoresis and ethidium bromide staining. PCR products were confirmed by direct DNA sequencing. A negative (water) control was included in 15 each PCR assay. All samples with negative results were subjected to PCR assay for RET gene as a control for the amplifiable quality of the serum DNA samples. The RET gene sequence which encodes receptor tyrosine kinase, is normally present in circulating blood of healthy individuals (Matisa-Guiu 1998).

20

Immunohistochemical staining and evaluation

Monoclonal antibody to β-catenin (C19220) was purchased from Transduction Laboratories (U.S.A.). The antibody was produced against the C-terminal of a mouse β-catenin protein (a.a. 571-581), and is reactive to β-catenin of human, rat and mouse species. Tissue sections with 4 µm thickness were placed on silane-coated (Sigma 25 Chemicals, St. Louis, MO) glass slides, air dried overnight and rehydrated with xylene and graded alcohol. Antigen retrieval and immunochemical staining was performed in the Ventana-ES automated immunostainer (Ventana, Tucson, Az) as described. The sections were counterstained with Harris haematoxylin and mounted with permount after dehydration in graded alcohol. The negative control was done by 30 replacing β-catenin antibody with TBS. Positive signals were evaluated in 4 fields under a light microscope at 10x40 magnification, without knowledge of the clinical

outcome. The results were evaluated by two independent observers manually and the data were expressed as IHC score obtained by multiplying "percentage of positive cells" by "staining intensity" according to Remmeli and Schicketanz with slight modification (Remmeli & Schicketanz, 1993; Wong et al., 2001). In this study, the 5 IHC scores were presented as follows: “-“ = no expression, 1 + = weak expression, 2 + = moderate expression 3 + = strong expression and 4 + = very strong expression.

Quantitative Analysis of plasma β -catenin RNA by Real-time RT-PCR

Copy numbers of plasma β -catenin RNA were measured by real-time RT-10 PCR, using the TagMan detection system (Heid et al., 1996). The amount of fluorescent product at any given cycle within the exponential phase of PCR is proportional to the initial number of template copies. The reactions were recorded and analyzed using an ABI Prism 7700 sequence detector equipped with a 96-well 15 thermal cycler (Perkin-Elmer Applied Biosystems, UK). Briefly, RNA samples (50-100 ng) were incubated with 0.01 units of uracil N-glycosylase (2 min at 50°C) and reverse-transcribed in a 25- μ l oligo(dT)-primed reaction at 60°C for 30 min. The cDNA templates were then subjected to a 5-min initial denaturation at 92°C prior to 20 40 cycles of PCR (92°C for 20 s and 62°C for 1 min, per cycle) in the presence of forward and reverse primers, then labeled with the fluorescent quenching group 6-carboxyfluorescein at the 5' end and the fluorescent quencher molecule at the 3' end.

Table 1: Sequence of primers used in the PCR reactions.

Primer size	Nucleotide sequence (5' to 3')	Design	product
5	1 sense: ATTTGATGGAGTTGGACATGG antisense: AGCTACTTGTCTTGAGTGAA	Within exon 3 of β -Catenin gene	224 bp
	2 sense: TGATTGATGGAGTTGGACAT antisense: CATTGCATACTGTCCATCAAT	Intron-spanning between exon 3 & 4 of β -Catenin gene	DNA: 450 bp cDNA: 250 bp
10	3 sense: AAATCGTGCCTGACATTAAGG antisense: ATGATGGAGTTGAAGGTAGTT	Intron-spanning between exon 4 & 5 of β -actin gene	DNA: 324 bp cDNA: 230 bp

Table 2. Correlation of plasma β -catenin RNA in colorectal adenoma and carcinoma patients with nuclear β -catenin expression (IHC scores) in their respective lesions.

Patients	Sex	Age	Diagnosis	Duke's stage	Size of lesion	Plasma	IHC of
						β -catenin	β -catenin
20	1	F 65	granulation tissue	N.A.	N.A.	-	-
	2	F 68	granulation tissue	N.A.	N.A.	-	-
25	3	F 59	dilated lymphatic space	N.A.	N.A.	-	-
	4	F 68	adenoma, moderate dys	N.A.	N.A.	+	+
30	5	F 75	adenoma, mild dys	N.A.	N.A.	+	++
	6	M 82	adenoma, mild dys	N.A.	N.A.	+	+
35	7	F 61	adenoma, moderate dys	N.A.	5 mm	+	+
	8	M 68	adenoma, moderate dys	N.A.	4 mm	+	+
40	9	F 77	adenoma, moderate dys	N.A.	N.A.	+	++
	10	M 72	adenoma, moderate dys	N.A.	10 mm	-	++
45	11	M 51	adenoma, mild dys	N.A.	N.A.	+	+
	12	F 81	adenoma, moderate dys	N.A.	N.A.	+	+
50	13	M 67	adenoma, moderate dys	N.A.	72 mm ³	+	++
	14	M 75	adenoma, moderate dys	N.A.	672 mm ³	-	++
55	15	M 70	adenoma, mild dys	N.A.	N.A.	+	+
	16	M 78	adenoma, severe dys	N.A.	1500 mm ³	-	+++
60	17	F 73	adenoma, severe dys	N.A.	1200 mm ³	+	+++
	18	M 59	adenocarcinoma	B	91 cm ³	+	+
65	19	F 56	adenocarcinoma	C	90 cm ³	+	+
	20	F 67	adenocarcinoma	C	108 cm ³	+	+
70	21	F 75	adenocarcinoma	C	100 cm ³	+	+++
	22	F 92	adenocarcinoma	N.A.	N.A.	+	++++
75	23	F 79	adenocarcinoma	N.A.	N.A.	+	++
	24	F 76	adenocarcinoma	B	88 cm ³	+	++
80	25	M 82	adenocarcinoma	D	115 cm ³	+	+
	26	F 77	adenocarcinoma	B	346 cm ³	+	+
85	27	F 73	adenocarcinoma	A	21 cm ³	+	+++
	28	F 82	adenocarcinoma	N.D.	N.D.	+	++++
90	29	F 80	adenocarcinoma	B	130 cm ³	+	++
	30	M 77	adenocarcinoma	B	155 cm ³	+	+++
95	31	M 62	adenocarcinoma	B	167 cm ³	+	++
	32	F 85	adenocarcinoma	B	143 cm ³	+	+++

dys: dysplasia; N.A.: not applied; N.D.: not determined.

Table 3: Primers used in the PCR reactions.

Primer	Nucleotide sequence (5' to 3')	Design	Product size
5	1 sense: TCAATGGGTATATCACAGAT antisense: CTGCATTCTGACTTCACTAA	In intron 2 and 3 of β-Catenin gene	359 bp
	2 sense: CCTCTGCGGTGCCAAGCCTC antisense: TGTGGGCAAACCTGTGGTAGCA	Within exon 11 of RET gene	156 bp

10

Table 4. Patients record

Patient	Sex	Age	Diagnosis	Duke's stage	Size of lesion
1	M	23	adenoma, severe dys	N.A.	75mm ³
	F	48	adenoma, moderate dys	N.A.	N.A.
15	M	67	adenoma, moderate dys	N.A.	168mm ³
	M	67	adenoma, severe dys	N.A.	80mm ³
20	M	76	adenoma, severe dys	N.A.	63mm ³
	F	62	adenoma, mild dys	N.A.	N.A.
25	M	85	adenoma, severe dys	N.A.	153mm ³
	F	81	adenoma, moderate dys	N.A.	96mm ³
30	F	58	adenoma, moderate dys	N.A.	48mm ³
	F	68	adenoma, moderate dys	N.A.	528mm ³
35	M	62	adenocarcinoma	B	182cm ³
	M	67	adenocarcinoma	B	72cm ³
40	M	83	adenocarcinoma	B	43cm ³
	M	45	adenocarcinoma	C	67cm ³
45	M	52	adenocarcinoma	C	41cm ³
	F	71	adenocarcinoma	C	64cm ³
50	M	80	adenocarcinoma	C	47cm ³
	M	61	adenocarcinoma	N.D.	N.A.
55	F	70	adenocarcinoma	A	13cm ³
	M	69	adenocarcinoma	B	120cm ³
60	M	61	adenocarcinoma	C	384cm ³
	F	72	adenocarcinoma	A	9cm ³
65	M	76	adenocarcinoma	N.D.	N.A.
	M	76	adenocarcinoma	C	88cm ³
70	M	70	adenocarcinoma	B	23cm ³

dys: dysplasia; N.A.: not applied; N.D.: not determined

40

While various embodiments are disclosed herein, it should be understood that they have been presented by way of example only, and not limitation. Thus, the breadth and scope of the invention(s) should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents. Moreover, the above advantages and features are affected in described embodiments, but shall not limit the application of the claims to processes and structures accomplishing any or all of the above advantages.

Furthermore, teachings from the following references are incorporated herein by reference for all purposes:

Anker, P., Lefort, F., Vasioukhin, V., Lyautey, J., Lederrey, C., Chen, X.Q., Stroun, M., Mulcahy, H.E. and Farthing, M.J. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. *Gastroenterology* 112: 1114-1120, 1997.

Chen, X. Q., Bonnefoi, H., Pelte, M-F., Lyautey, J., Lederrey, C., Movarekhi, S., Schaeffer, P., Mulcahy, H. E., Meyer, P., Stroun, M. and Anker, P. Telomerase RNA as a detection marker in the serum of breast cancer patients. *Clinical Cancer Research* 6: 3823-3826, 2000.

Hibi, K., Robinson, C.R., Booker, S., Wu, L., Hamilton, S.R., Sidransky, D. and Jen, J. Molecular detection of genetic alterations in the serum of colorectal cancer patients. 58: 1405-1407, 1998.

Kopreski, M. S., Benko, F. A., Kwak, L. W. and Gocke, C. D. Detection of tumor suppressor messenger RNA in the serum of patients with malignant melanoma. *Clinical Cancer Research* 5: 1961-1965, 1999.

Kopreski, M.S., Benko, F.A. and Gocke, C.D. Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. *Ann. N.Y. Acad. Sci.* 945: 172-178, 2001.

Lo, K. W., Lo, Y. M. D., Leung, S. F., Tsang, Y. S., Chan, L. Y. S., Johnson, P. J., Hjelm, N. M., Lee, J. C. K. and Huang, D. P. Analysis of cell-free Epstein-Barr virus-associated RNA in the plasma of patients with nasopharyngeal carcinoma. *Clinical Chemistry* 45: 1292-1294, 1999.

Matias-Guiu, X. RET protooncogene analysis in the diagnosis of medullary thyroid carcinoma and multiple endocrine neoplasia type II. *Advances in Anatomic Pathology* 5: 196-201, 1998.

Morin, P.J. β -catenin signaling and cancer. *Bioessays*, 21: 1021-1030, 1999.

Remmeli, W., Schicketanz, K.H. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs subjective grading IRS. *Pathol Res Pract* 189: 862-866, 1993.

Sozzi, G., Musso, K., Ratcliffe, C., Goldstraw, P., Pierotti, M.A. and Pastorino, U. Detection of microsatellite alterations in plasma DNA of non-small cell lung

cancer patients: a prospect for early diagnosis. *Clin. Cancer Res.* 5: 2689-2692, 1999.

5 von Knobloch, R., Hegele, A., Brandt, H., Olbert, P., Heidenreich, A. and Hofman, R. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. *Int.J. Cancer* 94: 67-72, 2001.

Willert, K. and Nusse, R. β -catenin: a key mediator of Wnt signaling. *Curr. Opin. Genet. Dev.* 8: 95-102, 1998.

10 Wong, S.C., Chan, K.C., Lee, K.C., Hsiao, W.L. Differential expressions of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis and tumor progression in invasive breast ductal carcinoma. *J Pathol* 194: 35-42, 2001.

15 Additionally, the section headings herein are provided for consistency with the suggestions under 37 CFR 1.77 or otherwise to provide organizational cues. These headings shall not limit or characterize the invention(s) set out in any claims that may issue from this disclosure. Specifically and by way of example, although the headings refer to a "Technical Field of the Invention," the claims should not be limited by the language chosen under this heading to describe the so-called field of the invention. Further, a description of a technology in the "Background of the Invention" is not to 20 be construed as an admission that technology is prior art to any invention(s) in this disclosure. Neither is the "Brief Summary of the Invention" to be considered as a characterization of the invention(s) set forth in the claims set forth herein. Furthermore, the reference in these headings, or elsewhere in this disclosure, to "invention" in the singular should not be used to argue that there is only a single point 25 of novelty claimed in this disclosure. Multiple inventions may be set forth according to the limitations of the multiple claims associated with this disclosure, and the claims, and their equivalents, accordingly define the invention(s) that are protected thereby. In all instances, the scope of the claims shall be considered on their own merits in light of the specification, but should not be constrained by the headings set 30 forth herein.

WHAT IS CLAIMED IS:



1. A method for detecting non-clinically diagnosed cancer in a patient, the method comprising:
 - 5 extracting blood serum or plasma from the patient;
 - detecting beta-catenin RNA in the blood serum or plasma; and
 - determining the presence of the cancer based on the detected beta-catenin RNA.
- 10 2. A method according to claim 1, wherein determining the presence of the cancer comprises determining the presence of colorectal cancer based on the detected beta-catenin RNA.
- 15 3. A method according to claim 2, wherein determining the presence of colorectal cancer comprises detecting pre-neoplastic colorectal polyps based on the detected beta-catenin RNA.
4. A method according to claim 1, wherein the RNA is derived from one of the group consisting of:
 - 20 gene-encoded beta-catenin,
 - gene-encoded alpha-catenin,
 - gene-encoded E-catherin, and
 - other gene-encoded beta-catenin associated proteins.
- 25 5. A method according to claim 1, wherein the patient is a human or animal.
6. A method for detecting non-clinically diagnosed cancer in a patient, the method comprising:
 - 30 extracting blood serum or plasma from the patient;
 - detecting beta-catenin DNA in the blood serum or plasma; and
 - determining the presence of the cancer based on the detected beta-catenin DNA.

7. A method according to claim 6, wherein determining the presence of the cancer comprises determining the presence of colorectal cancer based on the detected beta-catenin DNA.
- 5 8. A method according to claim 7, wherein determining the presence of colorectal cancer comprises detecting pre-neoplastic colorectal polyps based on the detected beta-catenin DNA.
9. A method according to claim 6, wherein the DNA is derived from one of the 10 group consisting of:
 - gene-encoded beta-catenin,
 - gene-encoded alpha-catenin,
 - gene-encoded E-catherin, and
 - other gene-encoded beta-catenin associated proteins.
- 15 10. A method according to claim 6, wherein the patient is a human or animal.
11. A method for detecting non-clinically diagnosed cancer in a patient, the 20 method comprising:
 - extracting blood serum or plasma from the patient;
 - detecting beta-catenin-associated gene RNA in the blood serum or plasma; and
 - determining the presence of the cancer based on the detected beta-catenin-associated gene RNA.
- 25 12. A method according to claim 11, wherein determining the presence of the cancer comprises determining the presence of colorectal cancer based on the detected beta-catenin-associated gene RNA.
13. A method according to claim 12, wherein determining the presence of 30 colorectal cancer comprises detecting pre-neoplastic colorectal polyps based on the detected beta-catenin-associated gene RNA.
14. A method according to claim 11, wherein the RNA is derived from one of the group consisting of:

gene-encoded beta-catenin,
gene-encoded alpha-catenin,
gene-encoded E-catherin, and
other gene-encoded beta-catenin associated proteins.


5

15. A method according to claim 11, wherein the patient is a human or animal.
16. A method for detecting non-clinically diagnosed cancer in a patient, the method comprising:
 - extracting blood serum or plasma from the patient;
 - detecting beta-catenin-associated gene DNA in the blood serum or plasma;
 - and
 - determining the presence of the cancer based on the detected beta-catenin-associated gene DNA.
17. A method according to claim 16, wherein determining the presence of the cancer comprises determining the presence of colorectal cancer based on the detected beta-catenin-associated gene DNA.
18. A method according to claim 17, wherein determining the presence of colorectal cancer comprises detecting pre-neoplastic colorectal polyps based on the detected beta-catenin-associated gene DNA.
19. A method according to claim 16, wherein the DNA is derived from one of the group consisting of:
 - gene-encoded beta-catenin,
 - gene-encoded alpha-catenin,
 - gene-encoded E-catherin, and
 - other gene-encoded beta-catenin associated proteins.
20. A method according to claim 16, wherein the patient is a human or animal.




BEST AVAILABLE COPY

Figure 1




BEST AVAILABLE COPY

Figures 2A-C




Figures 2D,E

BEST AVAILABLE COPY



BEST AVAILABLE COPY

Figures 3A-C



Figures 3D,E

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number
WO 2004/002294 A3

(51) International Patent Classification⁷: C07H 21/04, C12Q 1/68

(21) International Application Number: PCT/US2003/020587

(22) International Filing Date: 27 June 2003 (27.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/392,191 28 June 2002 (28.06.2002) US

(71) Applicant (for all designated States except US): HONG KONG UNIVERSITY OF SCIENCE & TECHNOLOGY [CN/CN]; Clear Water Bay, Kowloon, Hong Kong (CN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HSIAO, Wen-Luan Wendy [US/CN]; Flat 7-5A HKUST, Clear Water Bay, Kowloon, Hong Kong (CN). WONG, Sze-Chuen, Cesar [CN/CN]; Flat C, Floor 9, King's Court, 14-16 Village Road, Happy Valley, Hong Kong (CN).

(74) Agents: ORTEGA, James, H. et al.; Baker & McKenzie, Suite 2300, 2001 Ross Avenue, Dallas, TX 75201 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- with amended claims

(88) Date of publication of the international search report: 8 April 2004

Date of publication of the amended claims: 3 June 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PLASMA OR SERUM MARKER AND PROCESS FOR DETECTION OF CANCER

(57) Abstract: This disclosures provide, in one aspect, a method for detecting non-clinically diagnosed cancer in patient. In one embodiment, the method includes extracting blood serum or plasma from the patient, and then detecting beta-catenin RNA in the blood serum or plasma. In addition, in this embodiment, the method includes determining the presence of the cancer based on the detected beta-catenin RNA. In another aspect, this disclosure provides another embodiment of a method for detecting non-clinically diagnosed cancer in a patient. In this embodiment, the method includes extracting blood serum or plasma from the patient, and then detecting beta-catenin DNA in the blood serum or plasma. In addition, in this embodiment, the method includes determining the presence of the cancer based on the detected beta-catenin DNA. Related methods for detecting non-clinically diagnosed cancer in a patient comprising detecting beta-catenin-associated gene RNA, and beta-catenin-associated gene DNA, in the blood serum or plasma are also disclosed.

A3

WO 2004/002294

AMENDED CLAIMS

[received by the International Bureau on 08 April 2004 (08.04.04)
original claims 1-20 have been amended, 21-29 have been added.]

WHAT IS CLAIMED IS:

1. A method for detecting cancer in a patient, comprising:
extracting blood serum or plasma from the patient;
detecting the presence or absence of beta-catenin RNA in the blood serum or plasma;
and
determining the presence of the cancer based on the detected presence of beta-catenin RNA.
2. The method according to claim 1, whereby the cancer is colorectal cancer.
3. The method according to claim 2, whereby determining the presence of colorectal cancer comprises detecting pre-neoplastic colorectal polyps based on the detected presence of beta-catenin RNA.
4. The method according to claim 1, whereby the RNA is derived from one of the group consisting of:
gene-encoded beta-catenin,
gene-encoded alpha-catenin,
gene-encoded E-catherin, and
other gene-encoded beta-catenin associated proteins.
5. The method according to claim 1, whereby the patient is a human or animal.
6. A method for detecting cancer in a patient, comprising:
extracting blood serum or plasma from the patient;
detecting the presence or absence of beta-catenin DNA in the blood serum or plasma;
and
determining the presence of the cancer based on the detected presence of beta-catenin DNA.
7. The method according to claim 6, whereby the cancer is colorectal cancer.
8. The method according to claim 7, whereby determining the presence of colorectal cancer comprises detecting pre-neoplastic colorectal polyps based on the detected presence of beta-catenin DNA.
9. The method according to claim 6, whereby the DNA is derived from one of the group consisting of:
gene-encoded beta-catenin,

gene-encoded alpha-catenin,
gene-encoded E-catherin, and
other gene-encoded beta-catenin associated proteins.

10. The method according to claim 6, whereby the patient is a human or animal.
11. A method for detecting cancer in a patient, comprising:
 - extracting blood serum or plasma from the patient;
 - detecting the presence or absence of beta-catenin-associated gene RNA in the blood serum or plasma; and
 - determining the presence of the cancer based on the detected presence of beta-catenin associated gene RNA.
12. The method according to claim 11, whereby the cancer is colorectal cancer.
13. The method according to claim 12, whereby determining the presence of colorectal cancer comprises detecting pre-neoplastic colorectal polyps based on the detected beta-catenin-associated gene RNA.
14. The method according to claim 11, whereby the RNA is derived from one of the group consisting of:
 - gene-encoded beta-catenin,
 - gene-encoded alpha-catenin,
 - gene-encoded E-catherin, and
 - other gene-encoded beta-catenin associated proteins.
15. The method according to claim 11, whereby the patient is a human or animal.
16. A method for detecting cancer in a patient, comprising:
 - extracting blood serum or plasma from the patient;
 - detecting the presence or absence of beta-catenin-associated gene DNA in the blood serum or plasma; and
 - determining the presence of the cancer based on the detected presence of beta-catenin-associated gene DNA.
17. The method according to claim 16, whereby the cancer is colorectal cancer.

18. The method according to claim 17, whereby determining the presence of colorectal cancer comprises detecting pre-neoplastic colorectal polyps based on the presence of detected beta-catenin-associated gene DNA.

19. The method according to claim 16, whereby the DNA is derived from one of the group consisting of:

gene-encoded beta-catenin,

gene-encoded alpha-catenin,

gene-encoded E-catherin, and

other gene-encoded beta-catenin associated proteins.

20. The method according to claim 16, whereby the patient is a human or animal.

21. The method according to claims 2, 7, 12, or 16, whereby the colorectal cancer is colorectal carcinoma or colorectal adenoma.

22. A method of determining the presence of carcinoma, the presence of adenoma, or the absence of carcinoma and adenoma in a patient, comprising:

extracting blood serum or plasma from a patient;

measuring the relative amount of beta-catenin DNA or RNA in the blood serum or plasma of the patient and the relative amount of beta-catenin DNA or RNA in the blood serum or plasma of a control person known not to have carcinoma or adenoma;

determining a ratio of the amount of beta-catenin DNA or RNA detected in the blood serum or plasma of the patient to the amount of beta-catenin DNA or RNA detected in the blood serum or plasma of a control person known not to have carcinoma or adenoma, whereby the ratio of approximately 30-80 indicates the presence of adenoma, the ratio of approximately above 500 indicates the presence of carcinoma, and the ratio of approximately 1 indicates the absence of carcinoma and adenoma.

23. The method according to claim 22, whereby the carcinoma is colorectal carcinoma.

24. The method according to claim 22, whereby the adenoma is colorectal adenoma.

25. The method according to claim 22, whereby the DNA or RNA is derived from one of the group consisting of:

gene-encoded beta-catenin,

gene-encoded alpha-catenin,

gene-encoded E-catenin, and
other gene-encoded beta-catenin associated proteins.

26. The method according to claim 22, whereby the ratio of 30 indicates the presence of adenoma.

27. The method according to claim 22, whereby the ratio of 598 indicates the presence of carcinoma.

28. The method according to claim 22, whereby the relative amount of beta-catenin DNA or RNA in the blood serum or plasma of the patient and the relative amount of beta-catenin DNA or RNA in the blood serum or plasma of a control person known not to have carcinoma or adenoma is measured using real time reverse transcription-polymerase chain reactions.

29. The method according to claims 1, 6, 11, or 16, whereby the detecting step is accomplished using reverse transcription-polymerase chain reactions (RT-PCR).

24

BEST AVAILABLE COPY

AMENDED SHEET (ARTICLE 19)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.